- Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
Apr 30, 2026 · seekingalpha.com
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
- Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Apr 30, 2026 · globenewswire.com
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Strategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disorders Cash position of CHF 1.6 million at December 31, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2025 financial results for the period ended December 31, 2025, and provided a corporate update.
- ADDEX REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Apr 30, 2026
GABAB PAM CHRONIC COUGH CANDIDATE CONTINUED TOWARDS CLINIC AFTER DEMONSTRATING ROBUST ANTI-TUSSIVE ACTIVITY IN MULTIPLE DISEASE MODELS CONTINUED TO REPOSITION DIPRAGLURANT MGLU5 NAM FOR BRAIN INJURY RECOVERY ENTERED OPTION AND COLLABORATION AGREEMENT WITH SINNTAXIS FOR EXCLUSIVE LICENSE TO INTELLECTUAL PROPERTY COVERING THE USE OF MGLU5 NAM IN BRAIN INJURY RECOVERY REGAINED RIGHTS TO PHASE 2 MGLU2 PAM ASSET, ADX71149 PARTNER, INDIVIOR ADVANCED GABAB PAM SUBSTANCE USE DISORDERS PROGRAM SUCCESSFULLY THROUGH IND ENABLING STUDIES STRATEGIC INVESTMENT IN STALICLA SA, CONFIRMING COMMITMENT TO ADVANCING INNOVATIVE TREATMENTS FOR NEUROLOGICAL DISORDERS CASH POSITION OF CHF 1.6 MILLION AT DECEMBER 31, 2025 AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR GENEVA, SWITZERLAND, APRIL 30, 2026 - ADDEX THERAPEUTICS (SIX AND NASDAQ: ADXN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A PORTFOLIO OF NOVEL SMALL MOLECULE ALLOSTERIC MODULATORS FOR NEUROLOGICAL DISORDERS, TODAY REPORTED ITS FULL-YEAR 2025 FINANCIAL RESULTS FOR THE PERIOD ENDED DECEMBER 31, 2025, AND PROVIDED A CORPORATE UPDATE.
- Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Apr 29, 2026 · globenewswire.com
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model.
- ADDEX GABAB PAM CANDIDATE DEMONSTRATES SOLID ANTI-TUSSIVE ACTIVITY IN BLEOMYCIN IPF-RELATED CHRONIC COUGH MODEL
Apr 29, 2026
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR GENEVA, SWITZERLAND, APRIL 29, 2026 - ADDEX THERAPEUTICS (SIX: ADXN AND NASDAQ: ADXN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A PORTFOLIO OF NOVEL SMALL MOLECULE ALLOSTERIC MODULATORS FOR NEUROLOGICAL DISORDERS, ANNOUNCED TODAY ENCOURAGING PRECLINICAL DATA DEMONSTRATING ANTITUSSIVE ACTIVITY OF ITS GABAB POSITIVE ALLOSTERIC MODULATOR (PAM) CANDIDATE IN A BLEOMYCIN (BLM)-INDUCED IDIOPATHIC PULMONARY FIBROSIS (IPF) EXACERBATED CHRONIC COUGH MODEL.
- Addex Reports Neurosterix On Track To Complete Phase 1 Trial For Schizophrenia Drug NTX-253
Apr 23, 2026
(RTTNews) - Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, announced on Wednesday that the Phase 1 trial for NTX-253 in treating schizophrenia, developed by spun-out company Neurosterix, is on track to conclude by the second quarter of 2026.
NTX-253 is an investigational, potent, selective, orally-available positive allosteric modulator (PAM) of the muscarinic M4 receptor. By modulating dopamine signaling, the drug can reduce psychotic symptoms while avoiding the movement disorders associated with other dopamine antagonists.
The Phase 1 trial consists of two parts, namely a single ascending dose (SAD) part and multiple ascending dose (MAD) part.
The Part 1 SAD study will dose healthy participants with a single oral dose of NTX-253 in sequentially-escalating dose cohorts. The study will evaluate the impact of food on NTX-253 pharmacokinetics, and measure the drug's concentration in cerebrospinal fluid (CSF) to assess brain penetration. In contrast, the Part 2 MAD study will also dose two cohorts of schizophrenia patients, and will evaluate the safety, tolerability, and steady state pharmacokinetics with repeated doses. Participants will receive a daily oral-dosing with sequential dose escalation over 10 days.
Addex retains a 20% equity interest in Neurosterix, which is advancing a portfolio of allosteric modulator programs for schizophrenia, psychosis and mood-related disorders.
ADXN closed Wednesday at $6.60, down 6.12%. In the premarket, shares are trading at $6.88, down 4.24%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Apr 21, 2026
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model.
“These important data in non-human primates together with previously reported guinea pig data demonstrates the therapeutic potential of our highly selective, orally available GABAB PAM,” said Tim Dyer, CEO of Addex. “Chronic cough is a difficult to treat disease in need of novel therapeutics with the efficacy of baclofen, which is used off-label in these patients, but without the dose limiting side effects. Based on the data generated to date, we believe our GABAB PAM drug candidate has this therapeutic profile and the potential to be a once daily treatment for patients suffering from chronic cough.”
In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen.
As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate.
About GABAB activation and chronic cough
The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.
Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com
Contacts:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
PR@addextherapeutics.comMike Sinclair
Partner, Halsin Partners
+44 (0)7968 022075
msinclair@halsin.com
Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
- Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Apr 21, 2026 · globenewswire.com
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model.
- ADDEX GABAB PAM CANDIDATE DEMONSTRATES ROBUST ANTI-TUSSIVE ACTIVITY IN NON-HUMAN PRIMATE CHRONIC COUGH MODEL
Apr 21, 2026
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR GENEVA, SWITZERLAND, APRIL 21, 2026 - ADDEX THERAPEUTICS (SIX: ADXN AND NASDAQ: ADXN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A PORTFOLIO OF NOVEL SMALL MOLECULE ALLOSTERIC MODULATORS FOR NEUROLOGICAL DISORDERS, ANNOUNCED TODAY ROBUST ANTI-TUSSIVE ACTIVITY OF ITS NOVEL GAMMA-AMINOBUTYRIC ACID SUB-TYPE B RECEPTOR (GABAB) POSITIVE ALLOSTERIC MODULATOR (PAM) IN A NON-HUMAN PRIMATE (NHP) CHRONIC COUGH MODEL.
- Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Drops By 38.2%
Apr 13, 2026 · defenseworld.net
Addex Therapeutics Ltd. Sponsored ADR (NASDAQ: ADXN - Get Free Report) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totaling 6,748 shares, a decrease of 38.2% from the March 15th total of 10,913 shares. Currently, 0.6% of the shares of the stock are short
